BRCA Negative

BRCA Neagative

The KRAS-variant is an inherited genetic mutation associated with a family history of cancer, especially breast,1 ovarian,2 lung,3 as well as other cancers,4,5 and multiple cancers in the same individual.6,7

While BRCA is the most well-known and commonly tested mutation for Hereditary Breast and Ovarian Cancer (HBOC) families (i.e. those with multiple cases of breast and/or ovarian cancer on the same side of the family), the KRAS-variant is over 20x more common than BRCA genetic mutations.2, 6

Because BRCA is rare, many individuals from HBOC families test negative for this genetic mutation. However, the KRAS-variant is found in over 50% of HBOC families where no other known genetic mutations, including BRCA, have been found. If you have been tested for BRCA and other mutations for HBOC and have been found to be negative, you are eligible for KRAS-variant testing.  If you would like to order KRAS-variant testing directly, at the base cost of $295, please follow this link. If you would like to join a KRAS-variant study, please follow this link. You will be able to choose to get your KRAS-variant results at a discounted cost ($195) through the study.

MiraKind’s community for KRAS-variant positive patients is focused on better understanding the lifestyle and environmental factors that impact cancer risk for KRAS-variant individuals so that they may make informed decisions to protect their health.  Learn more about MiraKind’s open or future research studies that may be relevant to you.


Unlike BRCA, which is associated with earlier onset cancers, the KRAS-variant is primarily associated with cancer risk at or after menopause.

If you have a family history of cancer, learning whether you have the KRAS-variant can both help explain the genetic cause, and help you, together with your physician, make informed decisions about your health at many points in your life:


Determine whether higher-level breast cancer screening, such as breast MRI, is something to consider in addition to annual mammograms. If having a hysterectomy and you are peri-menopausal, discuss the pros and cons of ovary removal with follow-up hormone replacement therapy (HRT) with your physician.


Determine whether hormone replacement therapy at menopause could be protective against cancer if not otherwise contraindicated. Use the information to determine whether or not ovary removal makes sense for you at menopause.


Be aware that an increased risk of ovarian cancer increases the importance of ongoing gynecological care. Determine whether continuing on hormone replacement therapy may be beneficial.


Use your genetic information to ask for continued breast and gynecological screening. Determine whether continuing hormone replacement therapy may be beneficial.

If you’d like more information, please read our learn section or understanding your results page.

By enrolling in a MiraKind study, you can join our efforts to identify cancer prevention and risk-reduction strategies for individuals with the KRAS-variant. Being a study participant is FREE, and you can choose to get your KRAS-variant results at a discounted cost of $195.


The MiraKind community brings together individuals with the KRAS-variant to share their stories, learn from one other, and offer support.  Learn more. 

Spread the Word!

We need your help to let people know about the KRAS-variant. Hover over an image to share.

BRCA Negative vs. KRAS

Or click a button below:

  1. Paranjape, T., Heneghan, H., Lindner, R., Keane, F., Hoffman, A., Hollestelle, A., Dorairaj, J., Geyda, K., Pelletier, C., Nallur, S., et al. (2011). A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncology 12, 377-386.
  2. Ratner, E., Lu, L., Boeke, M., Barnett, R., Nallur, S., Chin, L., Pelletier, C., Blitzblau, R., Tassi, R., Paranjape, T., et al. (2010). A KRAS-variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 15, 6509-6515.
  3. Chin, L., Ratner, E., Leng, S., Zhai, R., Nullur, S., Babar, I., Muller, R., Straka, E., Su, L., Burki, E., et al. (2008). A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res 68, 8535-8540.
  4. Kazmi HR, Chandra A, Kumar S, Satyam LK, Gupta A, Nigam J, Srivastava M, Mittal B. (2016) A let-7 microRNA binding site polymorphism in the KRAS 3’UTR is associated with increased risk and reduced survival for gallbladder cancer in North Indian population. J Cancer Res Clin Oncol. 2016 Sep 12. [Epub ahead of print]
  5. Gutiérrez-Malacatt H, Ayala-Sanchez M, Aquino-Ortega X, Dominguez-Rodriguez J, Martinez-Tovar A, Olarte-Carrillo I, Martinez-Hernandez A, C CC, Orozco L, Cordova EJ. (2016) The rs61764370 Functional Variant in the KRAS Oncogene is Associated with Chronic Myeloid Leukemia Risk in Women. Asian Pac J Cancer Prev. 2016;17(4):2265-70.
  6. Pilarski, R., Patel, D., Weitzel, J., McVeigh, T., Dorairaj, J., Heneghan, H., Miller, N., Weidhaas, J., Kerin, M., McKenna, M., et al. (2012). A KRAS-variant is associated with risk of developing double primary breast and ovarian cancer. PLos ONE 7, e37891.
  7. McVeigh TP, Jung SY, Kerin MJ, Salzman DW, Nallur S, Nemec AA, Dookwah M, Sadofsky J, Paranjape T, Kelly O, Chan E, Miller N, Sweeney KJ, Zelterman D, Sweasy J, Pilarski R, Telesca D, Slack FJ, Weidhaas JB. (2015) Estrogen withdrawal, increased breast cancer risk and the KRAS-variant. Cell Cycle. 2015;14(13):2091-9. doi: 10.1080/15384101.2015.1041694. Epub 2015 May 11.